Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial

BACKGROUND: Elderly patients represent a major fraction of non-small cell lung cancer (NSCLC) patients in routine clinical practice, but they are still underrepresented in clinical trials. In particular, data regarding efficacy and safety in frail or elderly patients with respect to immunotherapy ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuon, Jonas, Hommertgen, Adriane, Krisam, Johannes, Lasitschka, Felix, Stenzinger, Albrecht, Blasi, Miriam, Bozorgmehr, Farastuk, Maenz, Martin, Kieser, Meinhard, Schneider, Marc, Thomas, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178741/
https://www.ncbi.nlm.nih.gov/pubmed/32321565
http://dx.doi.org/10.1186/s13063-020-04280-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178741/
https://www.ncbi.nlm.nih.gov/pubmed/32321565
http://dx.doi.org/10.1186/s13063-020-04280-8

Ejemplares similares